|
|
Volumn 16, Issue 7, 1998, Pages 615-
|
|
Genentech's anticancer Mab expected by November
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
CANCER IMMUNOTHERAPY;
CANCER REGRESSION;
CLINICAL TRIAL;
DRUG EFFECT;
FEMALE;
HUMAN;
MAJOR CLINICAL STUDY;
NOTE;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
ANTIBIOTICS, ANTINEOPLASTIC;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III;
DRUG APPROVAL;
FEMALE;
HUMANS;
PACLITAXEL;
RECEPTOR, ERBB-2;
UNITED STATES;
|
|
EID: 0031826373
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0798-615 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|